These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

366 related items for PubMed ID: 16128036

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. First report of the emergence of CTX-M-type extended-spectrum beta-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system.
    Lewis JS, Herrera M, Wickes B, Patterson JE, Jorgensen JH.
    Antimicrob Agents Chemother; 2007 Nov; 51(11):4015-21. PubMed ID: 17724160
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Prevalence of newer beta-lactamases in gram-negative clinical isolates collected in the United States from 2001 to 2002.
    Moland ES, Hanson ND, Black JA, Hossain A, Song W, Thomson KS.
    J Clin Microbiol; 2006 Sep; 44(9):3318-24. PubMed ID: 16954267
    [Abstract] [Full Text] [Related]

  • 6. Extended-spectrum beta-lactamases. An overview.
    Patterson JE.
    Postgrad Med; 2001 Feb; 109(2 Suppl):32-8. PubMed ID: 19667555
    [Abstract] [Full Text] [Related]

  • 7. [Beta-lactamases with a wide substrate spectrum in gram negative strictly anaerobic rods].
    Rokosz A, Sawicka-Grzelak A, Kot K, Pituch H, Meisel-Mikołajczyk F, Luczak M.
    Med Dosw Mikrobiol; 2000 Feb; 52(2):129-37. PubMed ID: 11107787
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Clinically important beta-lactamases of gram-negative bacteria: extended-spectrum beta-lactamases (ESBL)].
    Hrabák J.
    Epidemiol Mikrobiol Imunol; 2007 Aug; 56(3):103-11. PubMed ID: 17900058
    [Abstract] [Full Text] [Related]

  • 14. Role of beta-lactamase inhibitors in enterobacterial isolates producing extended-spectrum beta-lactamases.
    Bhattacharjee A, Sen MR, Prakash P, Anupurba S.
    J Antimicrob Chemother; 2008 Feb; 61(2):309-14. PubMed ID: 18174199
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Post-antibiotic and post-beta-lactamase inhibitor effects of ceftazidime plus sulbactam on extended-spectrum beta-lactamase-producing Gram-negative bacteria.
    Lavigne JP, Bonnet R, Michaux-Charachon S, Jourdan J, Caillon J, Sotto A.
    J Antimicrob Chemother; 2004 Apr; 53(4):616-9. PubMed ID: 14985275
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Resistance to newer beta-lactams and related ESBL types in gram-negative nosocomial isolates in Turkish hospitals: results of the multicentre HITIT study].
    Gür D, Gülay Z, Akan OA, Aktaş Z, Kayacan CB, Cakici O, Eraç B, Gültekin M, Oğünç D, Söyletir G, Unal N, Uysal S.
    Mikrobiyol Bul; 2008 Oct; 42(4):537-44. PubMed ID: 19149074
    [Abstract] [Full Text] [Related]

  • 20. [Beta-lactamases in laboratory and their role in resistance Part I.: Evolution of bacterial resistance mediated by beta-lactamases].
    Bedenić B.
    Lijec Vjesn; 2004 Oct; 126(11-12):314-24. PubMed ID: 16082890
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.